Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivonescimab + datopotamab deruxtecan
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
**Ivonescimab + Datroway** (datopotamab deruxtecan) is an investigational combination regimen consisting of ivonescimab, a first-in-class bispecific antibody targeting programmed cell death protein 1 (PD-1) and vascular endothelial growth factor A (VEGF-A), and Datroway, a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC) carrying a topoisomerase I inhibitor payload (DXd). Developed under a clinical trial collaboration between Summit Therapeutics, Akeso, AstraZeneca, and Daiichi Sankyo, this combination leverages the synergistic potential of dual immune checkpoint blockade and anti-angiogenesis alongside targeted cytotoxic chemotherapy. The regimen is primarily being evaluated in Phase III clinical trials as a first-line treatment for patients with advanced solid tumors, starting with triple-negative breast cancer (TNBC), as well as non-small cell lung cancer (NSCLC).
- Other names
- AK112 + Dato-DXdAK112 + DatrowayAK112 + datopotamab deruxtecanDato-DXd + ivonescimabDatroway + ivonescimabSMT112 + Dato-DXdSMT112 + DatrowaySMT112 + datopotamab deruxtecandatopotamab deruxtecan + ivonescimabivonescimab + Dato-DXdivonescimab + Datrowayivonescimab + datopotamab deruxtecan
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TACSTD2 (Tumor-associated calcium signal transducer 2)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ivonescimab + datopotamab deruxtecan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivonescimab + datopotamab deruxtecan.